Preeclampsia-The Problem

Globally, preeclampsia occurs in 2 to 8% of pregnancies. Hypertensive disease in pregnancy accounts for 26% of maternal deaths in Latin America and the Caribbean, while in Africa and Asia only 9%. In the United States the rate of preeclampsia increased 25% from 1987 to 2004, with almost a 7-fold increase in severe preeclampsia. The cost in the United States for a 12-month period has been estimated be $2.18 billion for women and $1.15 billion for treatment of infants born to mothers with preeclampsia.

Women with severe preeclampsia have a 20-fold increased of maternal mortality than if preeclampsia in a less sever form is present. Currently, there are two approaches to identify patients at increased risk for severe preeclampsia. The first is using historical data, and the second is using diagnostic ultrasound to evaluate the uterine artery blood flow. These options will be discussed below as both approaches have demonstrated a decrease in severe preeclampsia when treating patients with low-dose aspirin prior to 16 weeks of pregnanccy.

While there are RISK FACTORS for Preeclampsia,

 IT OFTEN OCCURS DURING THE 1ST PREGNANCY WITHOUT ANY WARNING!

Mild Preeclampsia-Diagnosis

Pregnant Women with No Previous History of Preeclampsia or Chronic Hypertension

Hypertension

Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg identified on 2 occasions 4 hours apart after 20 weeks of pregnancy in a patient with no previous history of preeclampsia and the new onset of 1 or more of the following laboratory findings:

• Protein in the urine of more than 300 mg in a 24-hour urine collection

• Protein in the urine on a dipstick of 2+ or greater

• Urine protein/creatinine ratio > 0.3 mg/mg or 30 mg/mmol

Pregnant Woman with Previous Hypertension

Definition: New onset of protein in the urine (see above) or other symptoms after 20 weeks of pregnancy

Pregnant Women with Previous Hypertension and Protein in the Urine

Definition: Worsening of the hypertension in the 3rd trimester of pregnancy with any of the above physical findings.

Associated with High Risk

for Maternal and Fetal

Complications

Is There A Role for Ultrasound to Identify Low-Risk Patients Who Could Develop Severe Preeclampsia?

While historic factors identify women at risk for preeclampsia, as described above, the majority of women who develop this disease HAVE NO RISK FACTORS.

An important study was published in the Canadian Medical Association Journal in 2008, followed by another large study from Europe in 2014,  have demonstrated the value of Doppler evaluation of the uterine arteries performed during the 1st trimester of pregnancy (11 to 14 weeks) to identify LOW RISK women who are at increased risk for severe preeclampsia.

The study in 2014 compared detection rates using historical factors vs abnormal uterine artery Doppler in  55,974 low risk patients and found the following:

• The detection rate for severe preeclampsia using uterine artery Doppler in low risk patients was 47.8% with a false-positive rate of 7.9%.  Therefore, to prevent one case of severe preeclampsia, 173 women would have to be treated with low-dose aspirin.

•  Conversely, using any of the historical risk factors the number of patients needed to be treated to prevent 1 case of severe preeclampsia varied between 1 in 256 to 1 in 1,429.

• Screening all patients using uterine artery Doppler also resulted in identifying patients at risk for the following:

• • Early growth restriction (see section on the website describing this problem) 39.2%, with a false-positive rate of 6.9%.
  • Stillbirth with a sensitivity of 14.5% and a false-positive rate of 8.7%.

• • An abnormal Doppler of the uterine artery obtained in low risk patients had a similar screening performance as high-risk patients.

Conclusions:

• Patients with no risk factors for preeclampsia, which makes up the majority of pregnant women, especially those having their first baby, have NO options for detecting their risk if historical factors are only used.

• Using Doppler evaluation of the uterine arteries in low risk patients detects as many patients who develop severe preeclampsia as those who have high-risk historical factors

• 1st trimester Doppler assessment of the uterine arteries to identify high-risk fetuses should be offered to all patients, irrespective of their risk using historical factors because abnormal values also identify other fetal conditions such as abnormal growth, as well as risks for a stillbirth.

The red overlay demonstrates the normal shape of the Doppler waveform of the uterine artery.  The images to the right demonstrate a "notch" that is abnormal.  The notch suggests that the vessels in the placenta have not developed properly, thus resulting in an increased resistance to blood flow.

Identification Low-Risk Patients by Historical Criteria  Who Have a High Risk for Preeclampsia Following Doppler Evaluation of the Uterine Arteries

Treatment Using Low-Dose Aspirin

Low-dose aspirin is the recommended treatment for patients at risk for preeclampsia. Researchers have recommended varying doses of aspirin ranging between 60 mg/day to 160 mg/day.

Since low-dose aspirin only is available in 81 mg tablets.  Therefore, the physican may prescribe either one 81 mg tablet or two 81 milligram tablets to be taken after the evening meal.

At the fetal diagnostic the protocol is as follows:

1st Trimester Evaluation of the Uterine Arteries (weeks 11 to 14)

• Take  two 81 mg tablets (162 milligrams) in the evening.

2nd Trimester Evaluation of the Uterine Arteries (weeks 16 to 22)

• If “notching persists into the 2nd trimester, the above regimen is continued until 36 weeks.

• If “notching has resolved, and is no longer present, then the aspirin is stopped.

• If “notching is detected then the aspirin regimen used in the 1st trimester is continued until 36 weeks.

• If “notching is no longer present, then the above aspirin regimen is continued.

• If the patient was not evaluated during the 1st trimester, but is noted to have abnormal Doppler of the uterine arteries, then the regimen is as follows:

• • Take  two 81 mg tablets (162 milligrams) in the evening.